Literature DB >> 25068589

Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells.

J E Vela Ramirez1, R Roychoudhury, H H Habte, M W Cho, N L B Pohl, B Narasimhan.   

Abstract

The functionalization of polymeric nanoparticles with ligands that target specific receptors on immune cells offers the opportunity to tailor adjuvant properties by conferring pathogen mimicking attributes to the particles. Polyanhydride nanoparticles are promising vaccine adjuvants with desirable characteristics such as immunomodulation, sustained antigen release, activation of antigen presenting cells (APCs), and stabilization of protein antigens. These capabilities can be exploited to design nanovaccines against viral pathogens, such as HIV-1, due to the important role of dendritic cells (DCs) and macrophages in viral spread. In this work, an optimized process was developed for carbohydrate functionalization of HIV-1 antigen-loaded polyanhydride nanoparticles. The carbohydrate-functionalized nanoparticles preserved antigenic properties upon release and also enabled sustained antigen release kinetics. Particle internalization was observed to be chemistry-dependent with positively charged nanoparticles being taken up more efficiently by DCs. Up-regulation of the activation makers CD40 and CD206 was demonstrated with carboxymethyl-α-d-mannopyranosyl-(1,2)-d-mannopyranoside functionalized nanoparticles. The secretion of the cytokines IL-6 and TNF-α was shown to be chemistry-dependent upon stimulation with carbohydrate-functionalized nanoparticles. These results offer important new insights upon the interactions between carbohydrate-functionalized nanoparticles and APCs and provide foundational information for the rational design of targeted nanovaccines against HIV-1.

Entities:  

Keywords:  HIV antigen; carbohydrates; dendritic cells; nanoparticles; nanovaccines; polyanhydrides; targeting

Mesh:

Substances:

Year:  2014        PMID: 25068589      PMCID: PMC4465578          DOI: 10.1080/09205063.2014.940243

Source DB:  PubMed          Journal:  J Biomater Sci Polym Ed        ISSN: 0920-5063            Impact factor:   3.517


  71 in total

Review 1.  C-type lectin receptors on dendritic cells and Langerhans cells.

Authors:  Carl G Figdor; Yvette van Kooyk; Gosse J Adema
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

Review 2.  The role of dendritic cell C-type lectin receptors in HIV pathogenesis.

Authors:  Stuart Turville; John Wilkinson; Paul Cameron; Joanne Dable; Anthony L Cunningham
Journal:  J Leukoc Biol       Date:  2003-09-02       Impact factor: 4.962

Review 3.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

4.  Carbohydrate analysis by a phenol-sulfuric acid method in microplate format.

Authors:  Tatsuya Masuko; Akio Minami; Norimasa Iwasaki; Tokifumi Majima; Shin-Ichiro Nishimura; Yuan C Lee
Journal:  Anal Biochem       Date:  2005-04-01       Impact factor: 3.365

5.  Tailoring the immune response by targeting C-type lectin receptors on alveolar macrophages using "pathogen-like" amphiphilic polyanhydride nanoparticles.

Authors:  Ana V Chavez-Santoscoy; Rajarshi Roychoudhury; Nicola L B Pohl; Michael J Wannemuehler; Balaji Narasimhan; Amanda E Ramer-Tait
Journal:  Biomaterials       Date:  2012-04-01       Impact factor: 12.479

6.  Synthesis of multivalent tuberculosis and Leishmania-associated capping carbohydrates reveals structure-dependent responses allowing immune evasion.

Authors:  Eun-Ho Song; Alex O Osanya; Christine A Petersen; Nicola L B Pohl
Journal:  J Am Chem Soc       Date:  2010-08-25       Impact factor: 15.419

7.  Macrophage receptors for influenza A virus: role of the macrophage galactose-type lectin and mannose receptor in viral entry.

Authors:  Jacqueline P Upham; Danielle Pickett; Tatsuro Irimura; E Margot Anders; Patrick C Reading
Journal:  J Virol       Date:  2010-01-27       Impact factor: 5.103

8.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

9.  Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.

Authors:  Bret D Ulery; Devender Kumar; Amanda E Ramer-Tait; Dennis W Metzger; Michael J Wannemuehler; Balaji Narasimhan
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

10.  Pseudo-mannosylated DC-SIGN ligands as potential adjuvants for HIV vaccines.

Authors:  Angela Berzi; Norbert Varga; Sara Sattin; Patrizio Antonazzo; Mara Biasin; Irene Cetin; Daria Trabattoni; Anna Bernardi; Mario Clerici
Journal:  Viruses       Date:  2014-01-27       Impact factor: 5.048

View more
  16 in total

1.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

2.  Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy.

Authors:  Timothy M Brenza; Shivani Ghaisas; Julia E Vela Ramirez; Dilshan Harischandra; Vellareddy Anantharam; Balaraman Kalyanaraman; Anumantha G Kanthasamy; Balaji Narasimhan
Journal:  Nanomedicine       Date:  2016-10-19       Impact factor: 5.307

3.  The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.

Authors:  Emad I Wafa; Sean M Geary; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  Acta Biomater       Date:  2017-01-04       Impact factor: 8.947

4.  pH-Responsive Microencapsulation Systems for the Oral Delivery of Polyanhydride Nanoparticles.

Authors:  Lindsey A Sharpe; Julia E Vela Ramirez; Olivia M Haddadin; Kathleen A Ross; Balaji Narasimhan; Nicholas A Peppas
Journal:  Biomacromolecules       Date:  2018-02-21       Impact factor: 6.988

Review 5.  Potential applications and human biosafety of nanomaterials used in nanomedicine.

Authors:  Hong Su; Yafei Wang; Yuanliang Gu; Linda Bowman; Jinshun Zhao; Min Ding
Journal:  J Appl Toxicol       Date:  2017-06-06       Impact factor: 3.446

6.  Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles.

Authors:  Julia E Vela-Ramirez; Jonathan T Goodman; Paola M Boggiatto; Rajarshi Roychoudhury; Nicola L B Pohl; Jesse M Hostetter; Michael J Wannemuehler; Balaji Narasimhan
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

7.  Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses.

Authors:  Julia E Vela Ramirez; Lorraine T Tygrett; Jihua Hao; Habtom H Habte; Michael W Cho; Neil S Greenspan; Thomas J Waldschmidt; Balaji Narasimhan
Journal:  J Biomed Nanotechnol       Date:  2016-06       Impact factor: 4.099

8.  Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity.

Authors:  Danielle A Wagner-Muñiz; Shannon L Haughney; Sean M Kelly; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

9.  Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf.

Authors:  Jodi L McGill; Sean M Kelly; Pankaj Kumar; Savannah Speckhart; Shannon L Haughney; Jamie Henningson; Balaji Narasimhan; Randy E Sacco
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

10.  Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.

Authors:  Luman Liu; Prakash Kshirsagar; John Christiansen; Shailendra K Gautam; Abhijit Aithal; Mansi Gulati; Sushil Kumar; Joyce C Solheim; Surinder K Batra; Maneesh Jain; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Biomed Mater Res A       Date:  2020-08-25       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.